JP2023532753A5 - - Google Patents
Info
- Publication number
- JP2023532753A5 JP2023532753A5 JP2023500304A JP2023500304A JP2023532753A5 JP 2023532753 A5 JP2023532753 A5 JP 2023532753A5 JP 2023500304 A JP2023500304 A JP 2023500304A JP 2023500304 A JP2023500304 A JP 2023500304A JP 2023532753 A5 JP2023532753 A5 JP 2023532753A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- chimeric anti
- patient
- dinutuximab
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20305766 | 2020-07-06 | ||
| EP20305766.6 | 2020-07-06 | ||
| PCT/GB2021/051721 WO2022008902A1 (en) | 2020-07-06 | 2021-07-06 | Method for treating a gd2-positive cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023532753A JP2023532753A (ja) | 2023-07-31 |
| JP2023532753A5 true JP2023532753A5 (https=) | 2024-07-10 |
Family
ID=71833285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023500304A Pending JP2023532753A (ja) | 2020-07-06 | 2021-07-06 | Ｇｄ２陽性がんを治療するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230295339A1 (https=) |
| EP (1) | EP4175988A1 (https=) |
| JP (1) | JP2023532753A (https=) |
| KR (1) | KR20230066320A (https=) |
| CN (1) | CN115835884A (https=) |
| AU (1) | AU2021303625A1 (https=) |
| BR (1) | BR112022027125A2 (https=) |
| CA (1) | CA3187938A1 (https=) |
| IL (1) | IL299504A (https=) |
| MX (1) | MX2023000384A (https=) |
| WO (1) | WO2022008902A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005206277B2 (en) | 2004-01-22 | 2011-06-23 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
| EP4218811A1 (en) | 2012-06-18 | 2023-08-02 | Apeiron Biologics AG | Method for treating a gd2 positive cancer |
| WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| US9840566B2 (en) | 2013-11-21 | 2017-12-12 | Apeiron Biologics Ag | Preparations and methods for treating a GD2 positive cancer |
| ES2768649T3 (es) * | 2013-11-21 | 2020-06-23 | Apeiron Biologics Ag | Preparaciones para tratar un cáncer positivo para GD2 |
| JP7614714B2 (ja) * | 2016-01-11 | 2025-01-16 | コーメディクス・インコーポレーテッド | 神経芽細胞腫及びその他のがん治療のための治療ナノ粒子 |
-
2021
- 2021-07-06 MX MX2023000384A patent/MX2023000384A/es unknown
- 2021-07-06 KR KR1020237004119A patent/KR20230066320A/ko active Pending
- 2021-07-06 US US18/004,339 patent/US20230295339A1/en active Pending
- 2021-07-06 CA CA3187938A patent/CA3187938A1/en active Pending
- 2021-07-06 JP JP2023500304A patent/JP2023532753A/ja active Pending
- 2021-07-06 BR BR112022027125A patent/BR112022027125A2/pt unknown
- 2021-07-06 EP EP21743231.9A patent/EP4175988A1/en active Pending
- 2021-07-06 CN CN202180048052.4A patent/CN115835884A/zh active Pending
- 2021-07-06 AU AU2021303625A patent/AU2021303625A1/en active Pending
- 2021-07-06 WO PCT/GB2021/051721 patent/WO2022008902A1/en not_active Ceased
- 2021-07-06 IL IL299504A patent/IL299504A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| JP2020090507A5 (https=) | ||
| JP2014500295A5 (https=) | ||
| JP2009539769A5 (https=) | ||
| JP2014077003A5 (https=) | ||
| JP2018528185A5 (https=) | ||
| JP2023551559A5 (https=) | ||
| Malpas et al. | Rubidomycin in acute leukaemia in adults | |
| JP2020523356A5 (https=) | ||
| JP2016515586A5 (https=) | ||
| JP2022527334A5 (https=) | ||
| JP6656397B2 (ja) | 抗腫瘍薬物の効果を有する併用薬物 | |
| JP2025148449A5 (https=) | ||
| JP2023532753A5 (https=) | ||
| CN117959315B (zh) | 化合物pgg作为krasg12d抑制剂mrt1133的增效剂联合治疗胰腺癌的应用 | |
| JP2020524164A5 (https=) | ||
| Clemm et al. | Combination chemotherapy with vinblastine, ifosfamide and cisplatin in bulky seminoma | |
| CN101588800B (zh) | 给药抗肿瘤化合物的方法 | |
| Ward et al. | Pacemaker related infective endocarditis from Staphylococcus lugdunensis: a case report | |
| South-East European Oncology Group (SEEOG) et al. | Phase II study of 4′-epi-doxorubicin in patients with untreated, extensive small cell lung cancer | |
| Miyata et al. | Fatal pulmonary veno-occlusive disease after chemotherapy for Burkitt's lymphoma. | |
| JP2018199726A5 (https=) | ||
| Brack et al. | Application for the Inclusion of Vinorelbine for the Treatment of Rhabdomyosarcoma as first line treatment on the WHO Essential Medicines List for Children 2021 | |
| RU2021126668A (ru) | Комбинированная терапия для применения в лечении рака | |
| Loehrer Sr et al. | Extensive small cell lung cancer: trials of Indiana University and the Hoosier Oncology Group |